X hits on this document

542 views

0 shares

0 downloads

0 comments

101 / 170

10

a presentation like this is some sort of a graphic that indicates the - I don't know whether

11

it would be risk or, something about how representative, the group of patients that have

12

been studied are, as compared to the general diabetic population. In this case, I think

13

from what I have read and heard, it's a relatively low-risk group of people and that's why

14

we are struggling with all these nuances of trying to extract extra information out of

15

things like the CPK.

1

would like to use it as monotherapy in patients where you wouldn’t have the problem

2

of having all sorts of other drugs, but given the recommendations for the level of glucose

3

control that are now in place, that by it’s very nature is likely to mean you are going to

4

have relatively recent onset or mild fairly stable non-progressive diabetic patients who

5

are going to have a relatively low risk of having cardiovascular events, and particularly

6

with the aggressive - with the advocacy of aggressive lipid lowering and blood pressure

7

control and so forth, the situation has gotten progressively worse as far as evaluating the

8

risk of a new drug.

18

perspective about the CK. When you monitor CK routinely in the study visits, that is not

19

looking for cardiac ischemia. That’s looking for Rhabdomyolysis really. So it's not, they

20

are just doing it routinely and you have to look at it the context of the individual’s

21

baseline, for example an African-American is going to have a higher baseline. anybody

22

who is on a Statin is going to have a higher CK at those study visits, which is why Statin

23

use becomes very relevant. We have to remember that we don’t use CKs drug for

24

myocardial ischemia anymore because they are not sensitive enough. That’s why we

100

9

So, one of the things that I think would be helpful for us to see if we have

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

16

DR. BURMAN: Thank you. Dr. Wyne, did you have a question?

17

DR. WYNE: I was just trying to put Eric’s question back into clinical

Document info
Document views542
Page views542
Page last viewedSat Dec 10 19:04:22 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments